Table 2. Associations of HLA-G 3’UTR SNPs with disease free survival and overall survival in 253 stage II-III CRC patients.
| Disease Free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|
| HLA-G 3’UTR Genotypes and genetic models | N | Relapses, N | Adjusted HR (95% CI) 1 | P-value | Dead, N | Adjusted HR (95% CI) 1 | P-value |
| +2960 14 bp INDEL (rs371194629) | |||||||
| Del/Del | 78 | 33 | 1 | - | 22 | 1 | - |
| Ins/Del | 115 | 32 | 0.59 (0.36–0.96) | 0.035 | 23 | 0.72 (0.40–1.30) | 0.269 |
| Ins/Ins | 60 | 17 | 0.61 (0.34–1.10) | 0.097 | 11 | 0.63 (0.30–1.30) | 0.212 |
| Dominant model (Ins/Del+Ins/Ins) | 175 | 49 | 0.60 (0.38–0.93) | 0.023 | 34 | 0.68 (0.40–1.18) | 0.171 |
| Recessive model (Ins/Ins) | 60 | 17 | 0.82 (0.48–1.39) | 0.457 | 11 | 0.76 (0.39–1.46) | 0.406 |
| +3003 T>C (rs1707) | |||||||
| T/T | 201 | 64 | 1 | - | 45 | 1 | - |
| T/C | 47 | 17 | 1.26 (0.73–2.17) | 0.401 | 10 | 1.01 (0.51–2.03) | 0.968 |
| C/C | 5 | 1 | 0.72 (0.10–5.22) | 0.744 | 1 | 1.15 (0.16–8.42) | 0.895 |
| Dominant model (T/C+C/C) | 52 | 18 | 1.21 (0.71–2.06) | 0.480 | 11 | 1.03 (0.53–2.00) | 0.942 |
| Recessive model (C/C) | 5 | 1 | 0.69 (0.10–4.96) | 0.709 | 1 | 1.14 (0.16–8.36) | 0.896 |
| +3010 C>G (rs1710) | |||||||
| C/C | 94 | 27 | 1 | - | 19 | 1 | - |
| C/G | 119 | 38 | 1.11 (0.68–1.83) | 0.670 | 24 | 0.99 (0.54–1.82) | 0.973 |
| G/G | 40 | 17 | 1.63 (0.89–3.00) | 0.115 | 13 | 1.60 (0.78–3.26) | 0.197 |
| Dominant model (C/G+G/G) | 159 | 55 | 1.24 (0.78–1.96) | 0.369 | 37 | 1.15 (0.66–2.00) | 0.632 |
| Recessive model (G/G) | 40 | 17 | 1.54 (0.90–2.63) | 0.117 | 13 | 1.61 (0.86–3.02) | 0.140 |
| +3027 C>A (rs17179101) | |||||||
| C/C | 225 | 77 | 1 | - | 50 | 1 | - |
| C/A | 27 | 5 | 0.54 (0.22–1.35) | 0.186 | 5 | 0.82 (0.33–2.05) | 0.666 |
| +3035 C>T (rs17179108) | |||||||
| C/C | 205 | 72 | 1 | - | 47 | 1 | - |
| C/T | 47 | 10 | 0.51 (0.26–0.99) | 0.045 | 8 | 0.66 (0.31–1.41) | 0.287 |
| +3142 G>C (rs1063320) | |||||||
| G/G | 93 | 27 | 1 | - | 19 | 1 | - |
| G/C | 119 | 37 | 1.05 (0.64–1.72) | 0.860 | 24 | 0.96 (0.52–1.75) | 0.882 |
| C/C | 41 | 18 | 1.65 (0.90–3.00) | 0.103 | 13 | 1.54 (0.76–3.15) | 0.233 |
| Dominant model (G/C+C/C) | 160 | 55 | 1.19 (0.75–1.89) | 0.465 | 37 | 1.10 (0.63–1.93) | 0.728 |
| Recessive model (C/C) | 41 | 18 | 1.61 (0.95–2.71) | 0.078 | 13 | 1.59 (0.84–2.98) | 0.153 |
| +3187 A>G (rs9380142) | |||||||
| A/A | 145 | 42 | 1 | - | 26 | 1 | - |
| A/G | 93 | 31 | 1.16 (0.73–1.86) | 0.529 | 23 | 1.26 (0.71–2.22) | 0.431 |
| G/G | 15 | 9 | 2.61 (1.24–5.50) | 0.012 | 7 | 2.96 (1.22–7.15) | 0.016 |
| Dominant model (A/G+G/G) | 108 | 40 | 1.33 (0.86–2.05) | 0.205 | 30 | 1.46 (0.86–2.48) | 0.162 |
| Recessive model (G/G) | 15 | 9 | 2.46 (1.19–5.05) | 0.015 | 7 | 2.71 (1.16–6.33) | 0.022 |
| +3196 C>G (rs1610696) | |||||||
| C/C | 106 | 40 | 1 | - | 29 | 1 | - |
| C/G | 107 | 26 | 0.61 (0.37–1.02) | 0.059 | 18 | 0.68 (0.37–1.24) | 0.206 |
| G/G | 40 | 16 | 0.96 (0.54–1.72) | 0.899 | 9 | 0.72 (0.34–1.52) | 0.388 |
| Dominant model (C/G+G/G) | 147 | 42 | 0.72 (0.46–1.12) | 0.142 | 27 | 0.69 (0.41–1.18) | 0.173 |
| Recessive model (G/G) | 40 | 16 | 1.18 (0.68–2.05) | 0.559 | 9 | 0.84 (0.41–1.72) | 0.630 |
1HRs (Hazard Ratios) adjusted for age, sex, tumour stage, first tumour site and type of adjuvant chemotherapy (FL plus or without OXA). Significant values (≤0.05) are shown in bold.